Telo Genomics Corp (TELO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Telo Genomics Corp (TELO) has a cash flow conversion efficiency ratio of 11.261x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-300.71K ≈ $-217.53K USD) by net assets (CA$-26.70K ≈ $-19.32K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Telo Genomics Corp market capitalisation for the company's overall valuation and market capitalisation.
Telo Genomics Corp - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Telo Genomics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Telo Genomics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telo Genomics Corp ranked by their cash flow conversion efficiency. Explore cash flow quality index of Telo Genomics Corp to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aberdeen International Inc.
TO:AAB
|
-0.705x |
|
GlucoTrack Inc
NASDAQ:GCTK
|
4.757x |
|
Searchlight Resources Inc
V:SCLT
|
-0.141x |
|
Imprimerie Chirat Société Anonyme
PA:MLIMP
|
N/A |
|
ACRUX Ltd
AU:ACR
|
-3.930x |
|
DGB Asia Bhd
KLSE:0152
|
0.007x |
|
LOBE SCIENCES LTD
F:6YX0
|
N/A |
|
Mlabs Systems Bhd
KLSE:0085
|
0.091x |
Annual Cash Flow Conversion Efficiency for Telo Genomics Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Telo Genomics Corp from 2013 to 2025. View current stock price of Telo Genomics Corp for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | CA$514.98K ≈ $372.53K |
CA$-2.33 Million ≈ $-1.68 Million |
-4.522x | -8.50% |
| 2024-06-30 | CA$590.06K ≈ $426.84K |
CA$-2.46 Million ≈ $-1.78 Million |
-4.168x | -314.10% |
| 2023-06-30 | CA$2.61 Million ≈ $1.89 Million |
CA$-2.63 Million ≈ $-1.90 Million |
-1.006x | -45.96% |
| 2022-06-30 | CA$2.60 Million ≈ $1.88 Million |
CA$-1.79 Million ≈ $-1.30 Million |
-0.690x | -130.08% |
| 2021-06-30 | CA$3.69 Million ≈ $2.67 Million |
CA$-1.10 Million ≈ $-799.00K |
-0.300x | +79.25% |
| 2020-06-30 | CA$775.25K ≈ $560.81K |
CA$-1.12 Million ≈ $-809.87K |
-1.444x | -560.26% |
| 2019-06-30 | CA$-1.04 Million ≈ $-755.83K |
CA$-327.84K ≈ $-237.15K |
0.314x | -96.93% |
| 2018-06-30 | CA$-314.02K ≈ $-227.16K |
CA$-3.21 Million ≈ $-2.32 Million |
10.211x | +387.79% |
| 2017-06-30 | CA$2.23 Million ≈ $1.61 Million |
CA$-7.90 Million ≈ $-5.71 Million |
-3.548x | -2455.34% |
| 2016-06-30 | CA$566.45K ≈ $409.76K |
CA$-78.65K ≈ $-56.89K |
-0.139x | +41.58% |
| 2015-06-30 | CA$449.24K ≈ $324.97K |
CA$-106.77K ≈ $-77.24K |
-0.238x | -233.65% |
| 2014-06-30 | CA$497.97K ≈ $360.22K |
CA$-35.47K ≈ $-25.66K |
-0.071x | +42.83% |
| 2013-06-30 | CA$535.16K ≈ $387.12K |
CA$-66.68K ≈ $-48.23K |
-0.125x | -- |
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive o… Read more